New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
16:24 EDTHPQ, UNH, MRK, JNJ, ZIP, CAR, X, DOLE, SKULOn The Fly: Closing Wrap
Stocks on Wall Street were significantly higher after U.S. lawmakers agreed on a deal to prevent falling off the fiscal cliff late last night. Several issues, including the debt ceiling, were pushed off by the agreement, but the stop-gap measure provided investors with enough temporary stability to send the market sharply higher at the open. The averages did not move far from their early levels and closed at the highs of the session... ECONOMIC EVENTS: In the U.S., Markit's final reading for December's purchasing managers' index came in at 54.0, which was up from 52.8 a month ago and beat expectations for a downward revision to 53.6. The ISM's December manufacturing PMI had a reading of 50.7, versus the expected 50.5, while the prices paid index came in at 55.5, versus the expected 50.8. A separate report showed construction spending fell 0.3% in November, versus an expected increase of 0.6%... COMPANY NEWS: Every member of the Dow Jones Industrial Average gained on the session, though UnitedHealth (UNH) rose only 30c, or 0.55%, to $54.54 and fellow healthcare companies Merck (MRK) and Johnson & Johnson (JNJ) were the average's other laggards. Shares of Hewlett-Packard (HPQ) lead the index, gaining 77c, or 5.4%, to $15.02... MAJOR MOVERS: Among the notable gainers was Zipcar (ZIP), which rose $3.94, or 47.82%, to $12.18 following its agreement to be acquired for $12.25 per share in cash by Avis Budget (CAR). Avis shares also gained 95c, or 4.79%, to $20.77. Also higher were shares of U.S. Steel (X), up $2.04, or 8.55%, to $25.89 after an upgrade to Outperform and a price target raise to $30 from $20 per share at Credit Suisse. Among noteworthy losers were shares of Dole Food (DOLE), which fell $1.54, or 13.43%, to $9.93 after the company said its fresh fruit business continues to experience declining earnings. Also lower was Skullcandy (SKUL), down 99c, or 12.71%, to $6.80 after Jefferies downgraded the stock two notches, to Underperform from Buy... INDICES: The Dow was up 308.41, or 2.35%, to 13,412.55; the Nasdaq was up 92.75, or 3.07%, to 3,112.26; and the S&P 500 was up 36.23, or 2.54%, to 1,462.42.
News For HPQ;UNH;MRK;JNJ;ZIP;CAR;X;DOLE;SKUL From The Last 14 Days
Check below for free stories on HPQ;UNH;MRK;JNJ;ZIP;CAR;X;DOLE;SKUL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 17, 2014
16:52 EDTUNHOn The Fly: Closing Wrap
Subscribe for More Information
16:13 EDTHPQHP appoints Whitman Chairman, Alcoa's Kleinfeld joins board
Subscribe for More Information
14:54 EDTJNJJohnson & Johnson weakness creates buying opportunity, says Argus
Subscribe for More Information
13:18 EDTUNHOn The Fly: Midday Wrap
Subscribe for More Information
10:56 EDTJNJJohnson & Johnson reports 18% passive stake in Minerva
Subscribe for More Information
09:13 EDTUNHUnitedHealth expects improving environment in 2016 and beyond
Expects to expand up to two dozen state exchanges in 2014. Project 6% commercial medical cost trend for 2016, with costs in line with company's plan and remains moderate. Expects margins to reach 7% this year, in line with original forecast. Expects Optum revenue to accelerate in 2H14, and particularly in Q4. Comments taken from Q2 earnings conference call.
06:28 EDTHPQHP increasing fire-safety audits in China, WSJ reports
Subscribe for More Information
06:18 EDTUNHUnitedHealth reports Q2 Optum revenue $11.7B
Subscribe for More Information
06:18 EDTUNHUnitedHealth raises low end of FY14 EPS to $5.50-$5.60 from $5.40-$5.60
Subscribe for More Information
06:18 EDTUNHUnitedHealth reports Q2 EPS $1.42, consensus $1.26
Reports Q2 revenue $32.57B, consensus $32B
July 16, 2014
16:00 EDTHPQOptions Update; July 16, 2014
iPath S&P 500 VIX Short-Term Futures down 70c to 27.25. Option volume leaders: AAPL FB GOOG AMZN TWTR TSLA C HPQ TWX INTC AMZN according to Track Data.
15:27 EDTUNHNotable companies reporting before tomorrow's open
Subscribe for More Information
14:32 EDTUNHUnitedHealth July 84 straddle priced for 2.8% move into Q2
14:14 EDTCARAvis to use space in Tesco lots under new test, Guardian reports
Subscribe for More Information
09:37 EDTHPQActive equity options trading on open
Subscribe for More Information
08:55 EDTHPQBarclays tech hardware analyst holds an analyst/industry conference call
Subscribe for More Information
08:55 EDTJNJJohnson & Johnson pullback a buying opportunity, says Leerink
Leerink views the post-earnings pullback in shares of Johnson & Johnson as a buying opportunity. The firm expects "several" more quarters of outperformance and raised its price target for the stock to $115 from $110. It keeps an Outperform rating on J&J.
08:05 EDTHPQHP has positive read through from Intel results, says Pacific Crest
Pacific Crest has an upward bias on its estimates for HP (HPQ) following Intel's (INTC) positive comments on the PC market. The firm thinks that HP's stock could jump another 20% if enterprise PC fundamentals continue to improve. It keeps an Outperform rating on HP.
07:25 EDTJNJJohnson & Johnson should be bought on pullbacks, says RBC Capital
RBC Capital believes that Johnson & Johnson reported strong Q2 results, and the company raised its estimates for the company. The firm continues to recommend buying the stock on pullbacks.
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use